These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26644398)

  • 1. OpenFDA: an innovative platform providing access to a wealth of FDA's publicly available data.
    Kass-Hout TA; Xu Z; Mohebbi M; Nelsen H; Baker A; Levine J; Johanson E; Bright RA
    J Am Med Inform Assoc; 2016 May; 23(3):596-600. PubMed ID: 26644398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications.
    Böhm R; von Hehn L; Herdegen T; Klein HJ; Bruhn O; Petri H; Höcker J
    PLoS One; 2016; 11(6):e0157753. PubMed ID: 27326858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse drug events and the Freedom of Information Act: an apple in Eden.
    Stang PE; Fox JL
    Ann Pharmacother; 1992 Feb; 26(2):238-43. PubMed ID: 1554939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events.
    Wang K; Wan M; Wang RS; Weng Z
    J Med Internet Res; 2016 Apr; 18(4):e76. PubMed ID: 27036325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration.
    Brajovic S; Piazza-Hepp T; Swartz L; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):565-70; discussion 571-2. PubMed ID: 22359404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
    Ball R; Robb M; Anderson SA; Dal Pan G
    Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA regulation of dietary supplements and requirements regarding adverse event reporting.
    Frankos VH; Street DA; O'Neill RK
    Clin Pharmacol Ther; 2010 Feb; 87(2):239-44. PubMed ID: 20032973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The US Food and drug administration: drug information resource for formulary recommendations.
    Marchand HC; Ros BJ; Fine AM; Kremzner ME
    J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT; Barash PG
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded FDA regulation of health and wellness apps.
    Kasperbauer TJ; Wright DE
    Bioethics; 2020 Mar; 34(3):235-241. PubMed ID: 31633831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safe Medical Devices Act: management guidance for hospital compliance with the new FDA requirements.
    Alder HC
    Hosp Technol Ser; 1993 Oct; 12(11):1-27. PubMed ID: 10129209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safe "cloudification" of large images through picker APIs.
    Bremer E; Kurc T; Gao Y; Saltz J; Almeida JS
    AMIA Annu Symp Proc; 2016; 2016():342-351. PubMed ID: 28269829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015.
    Gopal AD; Rathi VK; Teng CC; Del Priore L; Ross JS
    Ophthalmology; 2017 Aug; 124(8):1237-1246. PubMed ID: 28501378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bringing the FDA's Information to Market.
    Woloshin S; Schwartz LM
    Arch Intern Med; 2009 Nov; 169(21):1985-7. PubMed ID: 19933960
    [No Abstract]   [Full Text] [Related]  

  • 18. A case study in open source innovation: developing the Tidepool Platform for interoperability in type 1 diabetes management.
    Neinstein A; Wong J; Look H; Arbiter B; Quirk K; McCanne S; Sun Y; Blum M; Adi S
    J Am Med Inform Assoc; 2016 Mar; 23(2):324-32. PubMed ID: 26338218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
    Frank C; Himmelstein DU; Woolhandler S; Bor DH; Wolfe SM; Heymann O; Zallman L; Lasser KE
    Health Aff (Millwood); 2014 Aug; 33(8):1453-9. PubMed ID: 25092848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
    Goldman SA
    Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.